COVID-19 Patients' Psychiatric Drug Intervention

The National Exhibition and Convention Centre of Shanghai Fangcang Shelter Hospital were constructed as a temporary medical building for the admission and hospitalisation of infected patients with moderate and mild COVID-19 symptoms. It received 174,308 infected patients from 9 April 2022 to 31 May 2022. The infected patients were cured to discharge or transferred to a designated hospital for treatment with severe symptoms. The information of infected patients who used the drugs as listed (risperidone, olanzapine, quetiapine, paroxetine, sertraline, venlafaxine, flupentixol-melitracen, escitalopram oxalate, zolpidem tartrate, estazolam) was collected as the drug intervention group. Patients diagnosed of schizophrenia were mainly prescribed with risperidone, olanzapine and quetiapine. For depression diagnosis, patients were prescribed with paroxetine, sertraline, venlafaxine, flupentixol-melitracen or escitalopram oxalate according their individual specific symptom. Patients with insomnia were prescribed with zolpidem. And patients with symptoms of anxiety or sleep disorders were intervened with estazolam. The information was integrated when the infected individual used different drugs were classified listed as schizophrenia, depression, insomnia, anxiety or sleep disorder according to the symptom severity from severe to mild. A total of 6,218 individuals treated with the list drugs in the Fangcang shelter hospital were processed. Simultaneously, information of a corresponding comparable control group of 30,000 infected patients who has no listed psychiatric drug intervention was randomly drawn out based on the number of patients in the drug intervention group.